Name | N-{3-[7-{[6-(4-Hydroxy-1-piperidinyl)-3-pyridinyl]amino}-1-methyl-1,4-dihydropyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl}-3-(trifluoromethyl)benzamide |
---|---|
Synonyms |
Benzamide, N-[3-[1,4-dihydro-7-[[6-(4-hydroxy-1-piperidinyl)-3-pyridinyl]amino]-1-methylpyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)-
N-{3-[7-{[6-(4-Hydroxy-1-piperidinyl)-3-pyridinyl]amino}-1-methyl-1,4-dihydropyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl}-3-(trifluoromethyl)benzamide |
Description | XMU-MP-2 is a potent and selective BRK/PTK6 (breast tumor kinase) inhibitor with biochemical IC50 of 3.2 nM; inhibits the autophosphorylation of BRK Y342 in dose-dependent manner (maximum inhibition at 500 nM), abolishes phosphorylation levels of STAT3 Y705 and STAT5 Y694; blocks proliferation and survival of BRK-transformed Ba/F3 cells with IC50 of 29.7 nM; cooperates strongly with HER2 inhibitor or ER blockade to block breast cancer cell proliferation in vitro and in vivo. |
---|---|
References | References 1. Jiang J, et al. Cancer Res. 2017 Jan 1;77(1):175-186. View Related Products by Target Breast Tumor Kinase (BRK;PTK6) |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C32H33F3N8O2 |
Molecular Weight | 618.652 |
Exact Mass | 618.267883 |
LogP | 3.16 |
Index of Refraction | 1.659 |